Kiss of the muse for the chosen ones

De novo schizotypal traits and lifetime creative achievement are related to changes in divergent thinking during dopaminergic therapy in Parkinson's disease

Bertalan Polner, Helga Nagy, Annamária Takáts, S. Kéri

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Creativity can arise in some Parkinson's disease (PD) patients as a side effect of dopaminergic therapy. Schizotypal traits-subclinical traits resembling schizophrenia symptoms-can mediate some effects of dopaminergic drugs on cognition and neural activity. The goal of our study was to relate general intelligence, creative achievement and schizotypal traits to changes in performance on the Just Suppose test (from the Torrance battery), a task designed to measure verbal divergent thinking. Patients with PD and controls were examined at baseline, and at a follow-up session 12 weeks after pharmacotherapy had begun. Patients received dopamine agonist monotherapy (pramipexole and ropinirole). We observed significantly elevated positive schizotypy and impulsivity in PD at follow-up, while divergent thinking scores increased at trend level in the patient group. Linear regression analyses revealed that changes in various aspects of divergent thinking in PD were related to positive and disorganized schizotypy and lifetime creative achievement. The results highlight the relevance of schizotypal traits and lifetime creative achievement to the development of creativity in PD during dopaminergic therapy. The research draws attention to individual differences associated with a side effect of dopaminergic therapy in PD and also contributes to the understanding of the biological aspects of creativity.

Original languageEnglish
Pages (from-to)328-339
Number of pages12
JournalPsychology of Aesthetics, Creativity, and the Arts
Volume9
Issue number3
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Alprostadil
Parkinson Disease
Creativity
Therapeutics
Dopamine Agents
Impulsive Behavior
Dopamine Agonists
Intelligence
Individuality
Cognition
Thinking
Parkinson's Disease
Therapy
Kiss
Divergent Thinking
Muse
Linear Models
Schizophrenia
Regression Analysis
Drug Therapy

Keywords

  • Divergent thinking
  • Dopamine
  • Parkinson's disease
  • Pharmacotherapy
  • Schizotypy

ASJC Scopus subject areas

  • Applied Psychology
  • Developmental and Educational Psychology
  • Visual Arts and Performing Arts

Cite this

@article{59fd0255c1ec4de591d73713d3cd894b,
title = "Kiss of the muse for the chosen ones: De novo schizotypal traits and lifetime creative achievement are related to changes in divergent thinking during dopaminergic therapy in Parkinson's disease",
abstract = "Creativity can arise in some Parkinson's disease (PD) patients as a side effect of dopaminergic therapy. Schizotypal traits-subclinical traits resembling schizophrenia symptoms-can mediate some effects of dopaminergic drugs on cognition and neural activity. The goal of our study was to relate general intelligence, creative achievement and schizotypal traits to changes in performance on the Just Suppose test (from the Torrance battery), a task designed to measure verbal divergent thinking. Patients with PD and controls were examined at baseline, and at a follow-up session 12 weeks after pharmacotherapy had begun. Patients received dopamine agonist monotherapy (pramipexole and ropinirole). We observed significantly elevated positive schizotypy and impulsivity in PD at follow-up, while divergent thinking scores increased at trend level in the patient group. Linear regression analyses revealed that changes in various aspects of divergent thinking in PD were related to positive and disorganized schizotypy and lifetime creative achievement. The results highlight the relevance of schizotypal traits and lifetime creative achievement to the development of creativity in PD during dopaminergic therapy. The research draws attention to individual differences associated with a side effect of dopaminergic therapy in PD and also contributes to the understanding of the biological aspects of creativity.",
keywords = "Divergent thinking, Dopamine, Parkinson's disease, Pharmacotherapy, Schizotypy",
author = "Bertalan Polner and Helga Nagy and Annam{\'a}ria Tak{\'a}ts and S. K{\'e}ri",
year = "2015",
month = "8",
day = "1",
doi = "10.1037/a0039303",
language = "English",
volume = "9",
pages = "328--339",
journal = "Psychology of Aesthetics, Creativity, and the Arts",
issn = "1931-3896",
publisher = "American Psychological Association Inc.",
number = "3",

}

TY - JOUR

T1 - Kiss of the muse for the chosen ones

T2 - De novo schizotypal traits and lifetime creative achievement are related to changes in divergent thinking during dopaminergic therapy in Parkinson's disease

AU - Polner, Bertalan

AU - Nagy, Helga

AU - Takáts, Annamária

AU - Kéri, S.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Creativity can arise in some Parkinson's disease (PD) patients as a side effect of dopaminergic therapy. Schizotypal traits-subclinical traits resembling schizophrenia symptoms-can mediate some effects of dopaminergic drugs on cognition and neural activity. The goal of our study was to relate general intelligence, creative achievement and schizotypal traits to changes in performance on the Just Suppose test (from the Torrance battery), a task designed to measure verbal divergent thinking. Patients with PD and controls were examined at baseline, and at a follow-up session 12 weeks after pharmacotherapy had begun. Patients received dopamine agonist monotherapy (pramipexole and ropinirole). We observed significantly elevated positive schizotypy and impulsivity in PD at follow-up, while divergent thinking scores increased at trend level in the patient group. Linear regression analyses revealed that changes in various aspects of divergent thinking in PD were related to positive and disorganized schizotypy and lifetime creative achievement. The results highlight the relevance of schizotypal traits and lifetime creative achievement to the development of creativity in PD during dopaminergic therapy. The research draws attention to individual differences associated with a side effect of dopaminergic therapy in PD and also contributes to the understanding of the biological aspects of creativity.

AB - Creativity can arise in some Parkinson's disease (PD) patients as a side effect of dopaminergic therapy. Schizotypal traits-subclinical traits resembling schizophrenia symptoms-can mediate some effects of dopaminergic drugs on cognition and neural activity. The goal of our study was to relate general intelligence, creative achievement and schizotypal traits to changes in performance on the Just Suppose test (from the Torrance battery), a task designed to measure verbal divergent thinking. Patients with PD and controls were examined at baseline, and at a follow-up session 12 weeks after pharmacotherapy had begun. Patients received dopamine agonist monotherapy (pramipexole and ropinirole). We observed significantly elevated positive schizotypy and impulsivity in PD at follow-up, while divergent thinking scores increased at trend level in the patient group. Linear regression analyses revealed that changes in various aspects of divergent thinking in PD were related to positive and disorganized schizotypy and lifetime creative achievement. The results highlight the relevance of schizotypal traits and lifetime creative achievement to the development of creativity in PD during dopaminergic therapy. The research draws attention to individual differences associated with a side effect of dopaminergic therapy in PD and also contributes to the understanding of the biological aspects of creativity.

KW - Divergent thinking

KW - Dopamine

KW - Parkinson's disease

KW - Pharmacotherapy

KW - Schizotypy

UR - http://www.scopus.com/inward/record.url?scp=84938968242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938968242&partnerID=8YFLogxK

U2 - 10.1037/a0039303

DO - 10.1037/a0039303

M3 - Article

VL - 9

SP - 328

EP - 339

JO - Psychology of Aesthetics, Creativity, and the Arts

JF - Psychology of Aesthetics, Creativity, and the Arts

SN - 1931-3896

IS - 3

ER -